What's Happening?
Bavarian Nordic, a global vaccine company, has been awarded additional contract options valued at $97 million by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA). This contract is part of an ongoing
effort to supply a freeze-dried formulation of the JYNNEOS smallpox vaccine. The contract includes the manufacturing of additional bulk vaccine and the supply of freeze-dried doses, which are expected to be delivered in 2027. This development follows the use of liquid-frozen doses during the monkeypox outbreak in 2022-2023. The freeze-dried formulation, approved by the FDA in March 2025, offers advantages in terms of transportation, storage, and shelf life, making it suitable for long-term storage. Bavarian Nordic has been a key partner with the U.S. government in developing and supplying non-replicating smallpox vaccines, particularly for individuals with weakened immune systems.
Why It's Important?
This contract underscores the importance of public-private partnerships in enhancing public health preparedness against biological threats. The freeze-dried JYNNEOS vaccine formulation represents a significant advancement in vaccine logistics, offering improved storage and transportation capabilities. This is crucial for maintaining a robust national stockpile of vaccines that can be rapidly deployed in response to biological threats. The contract also highlights the U.S. government's commitment to investing in medical countermeasures that protect public health. For Bavarian Nordic, this contract not only boosts its financial outlook for 2026 but also solidifies its position as a leading supplier of vaccines to the U.S. government, potentially opening doors for future collaborations and contracts.
What's Next?
Bavarian Nordic is set to manufacture and deliver the remaining doses of the freeze-dried JYNNEOS vaccine by 2027. The company has upgraded its financial guidance for 2026, expecting increased revenue from its Public Preparedness business. As the U.S. government continues to prioritize public health preparedness, further contracts and collaborations with vaccine manufacturers like Bavarian Nordic may be anticipated. Additionally, the successful implementation of this contract could lead to further advancements in vaccine technology and logistics, enhancing the overall resilience of the U.S. public health infrastructure.
